Pharma Equity Group – Introduction to new CMO (Chief Medical Officer) Dr. Christopher M. Burton and dive into pipeline
Meet and ask questions to Dr. Christopher M. Burton from Reponex Pharmaceuticals, a fully owned subsidiary of Pharma Equity Group on 11 October 2023 at 11.00 AM.
Dr. Christopher M. Burton has extensive experience with clinical research and development. Mr. Burton will briefly introduce himself and present the pipeline.
Pharma Equity Group, listed on the Nasdaq Copenhagen Stock Exchange, places a strong emphasis on its portfolio company, Reponex Pharmaceuticals A/S. As a clinical-stage biopharmaceutical company, Reponex Pharmaceuticals is dedicated to developing innovative and effective treatments for diseases that have a profound impact on patients and society, especially in cases where current therapies are lacking or require improvement.
Pharma Equity Group’s primary focus lies in supporting and nurturing the growth of Reponex Pharmaceuticals within its portfolio. The company actively collaborates with Reponex Pharmaceuticals to help achieve its goals, leveraging the expertise of its experienced professionals in the life science industry, investment, and business development.
With a specialized investment focus on early-stage biotechnology companies, Pharma Equity Group recognizes the potential of Reponex Pharmaceuticals’ novel therapies for unmet medical needs. By maintaining Reponex Pharmaceuticals within its portfolio, Pharma Equity Group ensures a dedicated and strategic approach to driving its success.
Furthermore, Pharma Equity Group’s network of industry partners and advisors strengthens its commitment to Reponex Pharmaceuticals’ growth and development. The company’s overall strategy emphasizes creating a cost-efficient and flexible environment, enabling rapid mobilization of relevant resources—a key factor that drives the success of Reponex Pharmaceuticals’ innovative initiatives.
Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 12-09-2023 15.30 PM